Informed Consent: You are invited to participate in a research study entitled: Policy and Practice Considerations to Increase Access to and Representation in Oncology Clinical Trials. The purpose of this study is to understand how policy frameworks and practice level changes could enhance collaboration between academic and community oncologists to increase representative enrollment in oncology trials to achieve better health outcomes for all. "Representative enrollment" is defined as: Enrolling people who represent a wide range of demographics, including but not limited to race/ethnicity, socioeconomic status, and geographic location. This term is meant to reflect who participates or could potentially participate in clinical trials.

Your participation is voluntary, and you may withdraw at any time.

What to Expect: This survey will take approximately 10 minutes to complete. In the survey, you will be asked demographic questions including, but not limited to, participant race, age, gender, and role in the clinical trial process. You will be asked questions about perception of clinical trials, awareness of policies and guidance in clinical trials, experience participating in or working on a clinical trial, collaboration in clinical trials, and more. You may skip any questions you do not wish to answer, and you may exit the survey at any time.

Risks and Benefits: There are minimal risks associated with this research. There is a slight risk that participants may feel uncomfortable answering questions. You may refuse to answer any questions and may conclude the survey at any time. Data will be securely stored, and all data will be de-identified so there are minimal data risk issues. There is no guaranteed benefit to participating in this research. Participation in this research may contribute to understanding information surrounding effective policy and practice strategies to improve access to and representation in clinical trials, which may result in clinical trial findings being more generalizable to all populations. Data will be stored securely in NCCN until the end of the study. Results will be reported in aggregate (as a whole, not individually) form only. No personally identifiable information will be shared. Your responses will be anonymous and confidential.

If you have questions about this research, please contact:
  • Principal Investigator: Ashley Orr, MPH (orr@nccn.org)
  • Co-Investigator: Taneal D. Carter, DHSc, MPA, MS (carter@nccn.org)
  • Research Institution: National Comprehensive Cancer Network
  • IRB Contact: Pearl IRB

Question Title

1. By clicking "I Agree" below, you confirm that:
  • You are 18 years of age or older
  • You have read and understand the information above
  • You voluntarily agree to participate in this research study
 (Required.)

T